Craig-Hallum Initiates Coverage On MapLight Therapeutics with Buy Rating, Announces Price Target of $43

Benzinga Newsdesk www.benzinga.com Neutral 53.6%

Neg 0% Neu 53.6% Pos 0%

Craig-Hallum analyst Adam Vogel initiates coverage on MapLight Therapeutics (NASDAQ:MPLT) with a Buy rating and announces Price Target of $43.